A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B
PHASE2Active, not recruitingINTERVENTIONAL
Enrollment
80
Participants
Timeline
Start Date
June 1, 2023
Primary Completion Date
October 17, 2024
Study Completion Date
May 1, 2026
Conditions
Chronic Hepatitis B Virus
Interventions
DRUG
TVAX-008
TVAX-008
DRUG
Placebo
Placebo
Trial Locations (1)
10000
Peking University first hospital, Beijing
All Listed Sponsors
lead
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
INDUSTRY
NCT07190742 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B | Biotech Hunter | Biotech Hunter